头癌在欧洲的存活率:地理差异,时间趋势和长期存活率
G Gatta1, S Luttmann2, A Trama1
1Fondazione IRCCS Istituto Nazionale dei Tumori, Italy.
European journal of cancer (Oxford, England : 1990)
|September 13, 2025
概括
头癌 (HNC) 的生存率有所改善,但在欧洲仍然存在显著的地理差异. HNC患者面临着因其他原因死亡的更高风险,这突显了对综合护理的需求.
科学领域:
- 在瘤学瘤学.
- 流行病学 流行病学
- 公共卫生 公共卫生
背景情况:
- 头癌 (HNC) 是一种罕见的,异质的恶性瘤,治疗方案不断变化.
- HNC的风险因素与其他疾病重叠,使患者的治疗和结果复杂化.
- EUROCARE-6项目提供了一个更新生存数据和了解HNC死亡模式的平台.
研究的目的:
- 更新欧洲头癌存活率的地理差异.
- 分析随着时间的推移HNC存活的趋势.
- 将非HNC死亡率纳入头癌患者的长期生存估计.
主要方法:
- 分析了来自欧洲99个基于人口的癌症登记处的587,358例初级HNC病例 (1998-2013年诊断).
- 估计相对存活率 (RS) 到15年,按性别,年龄,国家和诊断期分层.
- 通过使用注册死亡原因数据,评估非HNC原因的过度死亡风险.
主要成果:
- 总体而言,15年的HNC的RS在男性中为30%,在女性中为40%.
- 在2002-2013年期间观察到的5年RS显著改善,特别是在口腔喉和唾液腺瘤中.
- 显著的地理生存差异被发现,东欧和波罗的海国家有较差的结果. HNC患者的非HNC死亡风险是2.1倍的.
结论:
- 头癌需要复杂的治疗方法和集中式护理模式.
- 需要努力在欧洲参考网络框架内减少地理生存差异.
- 在HNC患者中,非HNC死亡风险增加可能源于与生活方式因素 (如烟草和酒精使用) 相关的并发症.
更多相关视频
07:43Four-color Fluorescence Immunohistochemistry of T-cell Subpopulations in Archival Formalin-fixed, Paraffin-embedded Human Oropharyngeal Squamous Cell Carcinoma Samples
Published on: July 29, 2017
10.2K
07:29Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
12.2K
相关概念视频
01:21Cancer Survival Analysis
650
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
650
01:24Kaplan-Meier Approach
577
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
577
02:07Tumor Progression
7.2K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.2K
01:20Comparing the Survival Analysis of Two or More Groups
561
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
561